Yong-Jun Huh - Jul 22, 2024 Form 4 Insider Report for Artiva Biotherapeutics, Inc. (ARTV)

Role
Director
Signature
/s/ Neha Krishnamohan, Attorney-in-Fact
Stock symbol
ARTV
Transactions as of
Jul 22, 2024
Transactions value $
$30,614,401
Form type
4
Date filed
7/22/2024, 08:22 PM
Previous filing
Jul 18, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARTV Common Stock Conversion of derivative security +667K +191.26% 1.02M Jul 22, 2024 By GC Corp. F1, F2
transaction ARTV Common Stock Conversion of derivative security +330K +32.49% 1.35M Jul 22, 2024 By GC Corp. F1, F2
transaction ARTV Common Stock Other $3M +294K +21.85% $10.20* 1.64M Jul 22, 2024 By GC Corp. F2, F3
transaction ARTV Common Stock Purchase $20M +1.67M +101.61% $12.00* 3.31M Jul 22, 2024 By GC Corp. F2, F4
transaction ARTV Common Stock Conversion of derivative security +293K +125.9% 525K Jul 22, 2024 By GC Cell Corporation F1, F5
transaction ARTV Common Stock Conversion of derivative security +62.2K +11.84% 588K Jul 22, 2024 By GC Cell Corporation F1, F5
transaction ARTV Common Stock Other $2.61M +256K +43.63% $10.20* 844K Jul 22, 2024 By GC Cell Corporation F5, F6
transaction ARTV Common Stock Purchase $5M +417K +49.38% $12.00* 1.26M Jul 22, 2024 By GC Cell Corporation F4, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ARTV Series A Preferred Stock Conversion of derivative security -667K -100% 0 Jul 22, 2024 Common Stock 667K By GC Corp. F1, F2
transaction ARTV Series B Preferred Stock Conversion of derivative security -330K -100% 0 Jul 22, 2024 Common Stock 330K By GC Corp. F1, F2
transaction ARTV Series A Preferred Stock Conversion of derivative security -293K -100% 0 Jul 22, 2024 Common Stock 293K By GC Cell Corporation F1, F5
transaction ARTV Series B Preferred Stock Conversion of derivative security -62.2K -100% 0 Jul 22, 2024 Common Stock 62.2K By GC Cell Corporation F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.
F2 The shares are held directly by GC Corp. Mr. Yong-Jun Huh is Chief Executive Officer of GC Corp. GC Corp., a public Korean holdings company, is ultimately controlled by its board of directors, consisting of Mr. Yong-Jun Huh, Huh II-Sup, Park Yong-Tae and Kim Seok-Hwa. Each of these individual directors of GC Corp. may be deemed to share voting and investment power over the shares held by GC Corp. and each disclaims beneficial ownership of all shares held by such entity, except to the extent of any pecuniary interest therein.
F3 Represents the conversion of outstanding simple agreement for future equity in the amount of $3,000,000.00 into shares of the Issuer's common stock upon closing of the Issuer's IPO at a 15% discount to the IPO price.
F4 The shares were purchased in the Issuer's initial public offering.
F5 The shares are held directly by GC Cell Corporation. Mr. Yong-Jun Huh is Chief Executive Officer of GC Corp. GC Corp., a public Korean holdings company, which is the parent company of GC Cell Corporation and is ultimately controlled by its board of directors, consisting of Mr. Yong-Jun Huh, Huh II-Sup, Park Yong-Tae and Kim Seok-Hwa. Each of these individual directors of GC Corp. may be deemed to share voting and investment power over the shares held by GC Corp. and GC Cell Corporation and each disclaims beneficial ownership of all shares held by such entities, except to the extent of any pecuniary interest therein.
F6 Represents the conversion of outstanding simple agreement for future equity in the amount of $2,614,424.28 into shares of the Issuer's common stock upon closing of the Issuer's IPO at a 15% discount to the IPO price.